Managing High Risk Prostate Cancer Pt.2

Update: 2020-08-26

Description

Dr. Paul Sieber continues his conversation with Dr. Todd Cohen around managing the advanced prostate cancer patient. The use of somatic and germline testing to support decision making within the treatment algorithm are discussed. Medical management changes of positive mutation carriers and the commercial use of PARP inhibitors are also explored.

Send us a text

Comments

In Channel

Prostate Cancer Survivor - John Earp

2020-11-0523:53

HIFU and Prostate Cancer Pt. 2

2020-10-1518:36

HIFU and Prostate Cancer Pt. 1

2020-10-1526:06

Increased Collaboration With Pathologists Leads to Better Patient Decision Making

2020-09-2148:52

Prostate Cancer Survivor - Byron Sparkman

2020-09-0224:51

Managing High Risk Prostate Cancer Pt.2

2020-08-2623:56

Managing High Risk Prostate Cancer. Pt. 1

2020-08-1830:35

Racial Disparities in Prostate Cancer

2020-08-1028:02

Prioritizing Patient Care in the COVID Era Pt. 2

2020-05-1419:46

Prioritizing Patient Care in the COVID Era pt. 1

2020-05-1418:52

How Urologists Are Dealing With the COVID-19 Pandemic pt.4

2020-04-2031:09

How Urologists Are Dealing With the COVID-19 Pandemic pt. 3

2020-04-0928:21

How Urologists Are Dealing With the COVID-19 Pandemic Pt.2

2020-03-3027:46

Improving Resiliency During Times of Added Stress

2020-03-3031:46

How Urologists Are Dealing With the COVID-19 Pandemic Pt.1

2020-03-1814:10

The Future Role of Genetics in Precision Medicine

2020-02-2832:12

Men Get Cancer Too

2020-02-0522:25

Advanced Prostate Cancer Clinics

2019-11-1822:10

Improved Efficiency. The Benefits of an MBA.

2019-11-1820:49

Private Equity in Urology

2019-11-1822:34

00:00

Managing High Risk Prostate Cancer Pt.2

#box-pro-ellipsis-17619186690127{-webkit-line-clamp:2;}Managing High Risk Prostate Cancer Pt.2

Managing High Risk Prostate Cancer Pt.2

Myriad Genetics

Managing High Risk Prostate Cancer Pt.2